Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

View Full Paper
Ask AI
Bookmark
Share

Authors

PGPaolo GhiaSLSophie LeitchDWDavid Westerman

Discussion

Loading...

Member takes

Overview

Phase 1/1b study finds combination therapy achieves high undetectable minimal residual disease rates with good tolerability in CLL.

Key Points

  • This research evaluates the safety and efficacy of sonrotoclax combined with zanubrutinib in treatment-naive CLL/SLL patients.
  • Ongoing phase 1/1b study (BGB-11417-101)
  • Patients received sonrotoclax and zanubrutinib doses with follow-up assessments for safety and efficacy
  • Endpoints included overall response rate and undetectable minimal residual disease
  • Efficacy results show a 100% overall response rate in patients evaluated
  • Best undetectable minimal residual disease rate was 94% after treatment
  • Median time to response was 2.6 months with significant tolerability and safety profile

Cite This Study

Ghia et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86bhttps://doi.org/10.1182/blood-2025-3891
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  2. 2CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.2024 · 8 citations
  3. 3MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  4. 4Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.2026
  5. 5Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study2025 · 1 citations